Telmisartan80mg/hydrochlothiazide12.5mg (Micardis Plus) ABPM Study in China
Information source: Boehringer Ingelheim Pharmaceuticals
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypertension
Intervention: Telmisartan (Drug); Telmisartan/HCTZ (Drug)
Phase: Phase 3
Status: Completed
Sponsored by: Boehringer Ingelheim Pharmaceuticals Official(s) and/or principal investigator(s):
Boehringer Ingelheim Study Coordinator, Study Chair, Affiliation: Boehringer Ingelheim Shanghai
Summary
to evaluate the trough and peak effect of once daily MICARDIS PLUS? (Telmisartan 80mg /
hydrochlorot hiazide 12. 5 mg) by 24 ABPM in patients with mild to moderate essential
hypertension
Clinical Details
Official title: An Open-Label Study to Evaluate the Trough and Peak Effect of Once Daily Micardis Plus (Telmisartan 80mg / Hydrochlorothiazide 12.5 mg) by 24 ABPM in Patients With Mild to Moderate Essential Hypertension
Study design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Primary outcome: To assess trough/peak ratio of once daily Micardis plus by 24 ABPM in patients with mild to moderate essential hypertension
Secondary outcome: Smooth Index for DBP and SBP Change from the baseline in the ABPM endpoint: 24 hour mean, Daytime mean , nighttime mean, Morning mean, last 6-hr of the dosing interval mean SBP, DBP,MAP and HR.
Detailed description:
This study is designed as an open label study. After a 2-week placebo run-in phase, qualified
patien ts will be administered with telmisartan 80mg for 2 weeks, then forcefully titrated to
telmisartan 8 0mg and hydrochlorothiazide 12. 5mg fixed dose combination for 6 weeks. 24 hour
ABPM will be performe d at the end of placebo run-in period (baseline) and after 8 weeks of
active treatment
Study Hypothesis:
The primary analyses will be the calculation of trough to peak ratios (T/P ratio s) for DBP
and SBP. The T/P ratio will be calculated on the basis of changes in hourly means (related to
dosing time) from baseline (DeltaHM). Trough is defined as the mean of the last three hours
of the 24-hour dosing interval. Peak is the greatest reduction in hourly means in hours 2 to
8 after dosing. Thus, T/P is c alculated as T/P = mean (DeltaHM22 - DeltaHM24) / min (DeltaHM2 - DeltaHM8).
Comparison(s):
To assess trough/peak ratio of once daily Micardis plus by 24 ABPM in patients w ith mild to
moderate essential hypertension
Eligibility
Minimum age: 18 Years.
Maximum age: 80 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
1. History of mild-to-moderate essential hypertension defined by a mean seated DBP >=95
and <=109 mmHg, and SBP<180mmHg measured by manual cuff sphygmomanometer at visit 2
Note: The manual cuff value is calculated as the mean of three seated measurements
collected 2 minutes apart, after the patient has been seated quietly for 5 minutes.
For calculation of mean values by the investigator, decimal places should be rounded
to integers as usual (e. g. a DBP of 94. 7 would be rounded to 95 mmHg and a DBP of
109. 3 would be rounded to 109 mmHg)
2. Participants between 18 and 80 years of age
3. Ability to provide written informed consent 4. 24 hour mean DBP>=85mmHg at visit 3
5. Ability to stop any current antihypertensive therapy without risk to the patient
(investigators discretion)
Exclusion Criteria:
1. Patients taking more than three anti-hypertensive medications at the screening visit
2. Pre-menopausal women (last menstruation <= 1 year prior to start of screening):
- Who are not surgically sterile (hysterectomy, tubal ligation)
- Who are NOT practicing acceptable means of birth control or who do NOT plan to
continue using an acceptable method throughout the study. Acceptable methods of
birth control include IUD, oral, implantable or injectable contraceptives
3. Any woman:
- Who has a positive urine pregnancy test at screening (Visit 1)
- Who is nursing
4. Hepatic and/or renal dysfunction as defined by the following laboratory parameters:
- SGPT(ALT) or SGOT(AST) greater than two times the upper limit of normal
- Serum creatinine >3. 0 mg/dL (or 265mmol/L) or creatinine clearance <0. 6 ml/sec
5. Clinically relevant hypokalaemia or hyperkalaemia
6. Uncorrected volume depletion
7. Uncorrected sodium depletion
8. Hereditary fructose intolerance
9. Biliary obstructive disorders, cholestasis or moderate to severe hepatic
insufficiency
10. Known or suspected secondary hypertension
11. Bilateral renal artery stenosis; renal artery stenosis in a solitary kidney;
post-renal transplant patients, presence of only one functioning kidney
12. Congestive heart failure (NYHA functional class CHF III-IV refer to Appendix 11. 1)
13. Unstable angina within the past three months
14. Stroke within the past six months
15. Myocardial infarction or cardiac surgery within the past three months
16. PTCA within the past three months
17. Patients who have previously experienced symptoms characteristic of angiodema during
treatment with ACE inhibitor or angiotensin II receptor antagonists
18. Sustained ventricular tachycardia, atrial fibrillation, atrial flutter or other
clinically relevant cardiac arrhythmias as determined by the investigator
19. Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant
stenosis of the aortic or mitral valve
Locations and Contacts
Shanghai Ruijin Hospital, Shanghai 200025, China
Additional Information
Ending date: August 2006
Last updated: April 4, 2008
|
